PITTSBURGH--(BUSINESS WIRE)--RedPath Integrated Pathology, Inc., a molecular diagnostics company dedicated to the effective diagnosis of cancer, has announced that it has entered into a professional services agreement with Allegheny General Hospital (AGH), a leading healthcare provider in southwestern Pennsylvania. According to the agreement, pathologists from AGH and The Western Pennsylvania Hospital (WPH) have been trained at RedPath’s state-of-the-art molecular diagnostics laboratory in the diagnosis of pancreatic cyst fluid specimens collected by endoscopic ultrasound-guided, fine needle aspiration (FNA) and analyzed by RedPath’s proprietary PathFinderTG® mutational profiling technology. With the completion of training, the AGH/ WPH pathologists are certified to sign out PathFinderTG (PFTG) results on specimens sent to RedPath from hospitals, medical centers and endoscopy centers located throughout the United States. Additionally, AGH cytopathologists will also perform cytology analyses on these cyst fluids which will allow RedPath to expand further its test menu for pancreatic cysts.
